In the latest show of power from the Federal Trade Commission in the pharmaceutical space, Sanofi terminated its proposed acquisition of an exclusive license to Maze Therapeutics’ phase 2 developmental drug for Pompe disease just days after FTC announced it would sue to block the deal from occurring, alleging it would eliminate upcoming competition from lower-cost treatments. FTC alleged in an administrative complaint issued Monday (Dec. 11) that the proposed $755 million deal for Sanofi to acquire Maze’s still developing...